PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 4 | 1 | A33-36
Article title

Everolimus with exemestane in elderly breast cancer patients – case report

Content
Title variants
Languages of publication
EN
Abstracts
EN
Treating elderly patients suffering from metastatic breast cancer still constitutes a significant therapeutic problem. The possibility of administering everolimus in combination with exemestane appears to be a promising therapeutic option in the case of hormone-dependent cancers, without HER2 receptor overexpression.
Keywords
Discipline
Publisher
Journal
Year
Volume
4
Issue
1
Pages
A33-36
Physical description
References
  • Didkowska J, Wojciechowska U, Zatoński W. Malignant tumours in Poland in 2011. National Cancer Registry.
  • Pritchard KI, Gelmon KA, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor-positive HER2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol.
  • Baselga J, Campone M, Piccart M et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012; 366: 520-9.
  • Paplomata E, Zelnak A, O’Regan R. Ewerolimus: side effect profile and management of toxicities in breast cancer. Future Oncol. 2012; 8(6): 651-657.
  • Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 2012; 8(6): 651-7
  • Pritchard KI, Burris HA 3rd, Ito Y et al. Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13(6): 421-432.e8.
Document Type
report
Publication order reference
YADDA identifier
bwmeta1.element.psjd-85495246-3f3b-47fa-8c8c-ffb923f8f966
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.